Tag: everolimus

Adjuvant sunitinib in high-risk renal cell carcinoma after nephrectomy Sunitinib is a vascular endothelial growth factor pathway inhibitor used for treatment of metastatic renal cell carcinoma, however its efficacy in the setting of patients with non-metastatic renal cell carcinoma at high risk for recurrence after nephrectomy has not been largely...
1. Conversion at 4.5 months following kidney transplant from cyclosporine (a calcineurin inhibitor) to everolimus (a mTOR pathway inhibitor) maintains improved renal function at 5-year follow-up 2. Although post-conversion everolimus therapy was associated with an increased the rate of acute rejection, it was reversible and did not affect long term...
1. A metastatic anaplastic thyroid cancer with inactivation of tumor suppressor gene TSC2 and overactivation of the mammalian target of rapamycin (mTOR) pathway proved exquisitely sensitive to everolimus, an inhibitor of mTOR, providing 18 months of treatment response before development of acquired tumor resistance. 2. The resistant tumor harbored a...
1. In the BIOSCIENCE trial, a novel biodegradable polymer sirolimus-eluting stent (Orsiro) was non-inferior to the durable polymer everolimus-eluting stent with respect to cardiac death, target-vessel myocardial infarction (MI), and clinically-indicated target lesion revascularization. 2. Orsiro stents were associated with improved outcomes compared to durable polymer everolimus-eluting stents in...
In this section, we highlight the key high-impact studies, updates, and analyses published in medicine during the past week. Effect of Erythropoietin and Transfusion Threshold on Neurological Recovery After Traumatic Brain Injury Patients with traumatic brain injury (TBI) commonly develop anemia, which can cause secondary injury and worsen neurological outcomes. Erythropoietin has...
1. Compared to placebo, treatment with everolimus did not improve survival in patients with advanced hepatocellular carcinoma (HCC) who had previously failed sorafenib treatment.  2. Compared to placebo, everolimus treatment did not delay time to disease progression but did improve the disease control rate.  Evidence Rating Level: 1 (Excellent)    ...